Program
direclidine
Also written as “NBI-1117568”, “HTL0016878” and “HTL0016878.HCl Solution 10 mg”.
Its studies are mostly in Schizophrenia · Mania, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurocrine Biosciences | 65 open or running | phase 3since Apr 30, 2025 | Sep 14, 2022 | Oct 2027phase 3 · NCT06963034 |
| Nxera Pharma UK | 30 open or running | phase 1since Aug 3, 2017 | Aug 3, 2017 | none ahead |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2017First study: phase 1 study in HealthyNew to Nxera Pharma UKNxera Pharma UK · NCT03244228 · 120 enrolled · United Kingdom
- Apr 15, 2021Phase 1 study in Healthy SubjectsNxera Pharma UK · NCT04849286 · 16 enrolled · United Kingdom
- Jun 21, 2021Phase 1 study in Healthy SubjectsNxera Pharma UK · NCT04935320 · 15 enrolled · United Kingdom
- Sep 14, 2022Neurocrine Biosciences's first study: phase 2 study in SchizophreniaNew to Neurocrine BiosciencesNeurocrine Biosciences · NCT05545111 · 210 enrolled · United States
- Apr 30, 2025Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT06963034 · 284 planned · United States
- Jul 29, 20252 phase 3 studies in SchizophreniaNeurocrine Biosciences · NCT07114874, NCT07105098
- Nov 11, 2025Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT07227818 · 560 planned · United States, Puerto Rico, Serbia
- Dec 15, 2025Phase 2 study in ManiaNeurocrine Biosciences · NCT07288320 · 150 planned · United States
Ahead
- Oct 2027Primary completion: phase 3 study in SchizophreniaNeurocrine Biosciences · NCT06963034
- Nov 2027Primary completion: phase 3 study in SchizophreniaNeurocrine Biosciences · NCT07105098
- Feb 2028Primary completion: phase 2 study in ManiaNeurocrine Biosciences · NCT07288320
- Jul 2029Primary completion: phase 3 study in SchizophreniaNeurocrine Biosciences · NCT07227818
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07288320Mania · United States | 2 | Recruiting | Neurocrine Biosciences | Feb 2028 | 150 |
| NCT07227818Schizophrenia · United States, Puerto Rico, Serbia | 3 | Recruiting | Neurocrine Biosciences | Jul 2029 | 560 |
| NCT07114874Schizophrenia · United States, Bulgaria, Puerto Rico and more | 3 | Recruiting | Neurocrine Biosciences | Dec 2031 | 600 |
| NCT07105098Schizophrenia · United States, Bulgaria, Hungary and more | 3 | Recruiting | Neurocrine Biosciences | Nov 2027 | 284 |
| NCT06963034Schizophrenia · United States | 3 | Recruiting | Neurocrine Biosciences | Oct 2027 | 284 |
| NCT05545111Schizophrenia · United States | 2 | Completed | Neurocrine Biosciences | Jul 10, 2024 | 210 |
| NCT04935320Healthy Subjects · United Kingdom | 1 | Completed | Nxera Pharma UK | Oct 29, 2021 | 15 |
| NCT04849286Healthy Subjects · United Kingdom | 1 | Completed | Nxera Pharma UK | Dec 7, 2018 | 16 |
| NCT03244228Healthy · United Kingdom | 1 | Completed | Nxera Pharma UK | Sep 23, 2019 | 120 |
How it is read
Names in the registry
- “NBI-1117568”, 6 entries
- “HTL0016878”, 2 entries
- “HTL0016878.HCl Solution 10 mg”, 1 entry
- “HTL0016878.Citrate Capsule 10 mg”, 1 entry
Codes read as this program: HTL0016878.
Conditions, from the studies’ own filings
- Schizophrenia, 5 studies
- Mania, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.